Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 266-271

  Liu, Kevin K C ^a   Cornelius, Peter ^a   Patterson, Terrell A ^a   Zeng, Yuan ^a   Santucci, Stephanie ^a   Tomlinson, Elizabeth ^a   Gibbons, Colleen ^a   Maurer, Tristan S ^a   Marala, Ravi ^a   Brown, Janice ^a   Kong, Jimmy X ^a   Lee, Eunsun ^a   Werner, Wendy ^a   Wenzel, Zane ^a   Vage, Chandra ^a  

^a PFIZER INC   (United States)

Author keywords

5HT2c; Conformationally restricted; Dose responsive manner

Indexed keywords

ANTIOBESITY AGENT; CP 0808101; INDAN DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FOOD INTAKE; GENOTOXICITY; NONHUMAN; OBESITY; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; AZA COMPOUNDS; DOGS; DRUG DESIGN; HAPLORHINI; HUMANS; OBESITY; RATS; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 72049126966     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.112     Document Type: Article

References (18)

1. Hoyer D., Clarke D.E., and Fozard J.R. Pharmacol. Rev. 46 (1994) 157
2. Saxena P.R. Pharmacol. Rev. 66 (1994) 339
3. Nonogaki K., Strack A.M., Dallman M.F., and Tecott L.H. Nat. Med. 4 (1998) 1152
4. Sargent P.A., Sharpley A.L., Willians C., Goodall E.M., and Cowen P.J. Psychopharmacology 133 (1997) 309
5. Halford J.C., Harrold J.A., Lawton C.L., and Blundell J.E. Curr. Drug Targets 6 (2005) 201
6. Smith, S.; Prosser, W.; Donahue, D.; Anderson, C.; Shanahan, W. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, DC) 2006, Abst 344-OR.
7. Loke Y.K., Derry S., and Pritchard-Copley A. BMC Clin. Pharmacol. 2 (2002) 6
8. Nichlos D.E. Pharmacol. Ther. 101 (2004) 131
9. Kalgutkar A.S., Bauman J.N., McClure K.F., Aubrecht J., Cortina S.R., and Paralkar J. Bioorg. Med. Chem. Lett. 19 (2009) 1559
10. Blagg J. Ann. Rep. Med. Chem. 41 (2006) 353
11. Hopkins A.L., Groom C.R., and Alex A. Drug Discovery Today 9 (2004) 430
12. For the details of our biological assays and the spontaneous food intake model, please see: Chen, Hou.; Coffey, Steven Blair.; Lefker, Bruce Allen.; Liu, Kevin, K.-C. WO 2006103511, 2006.
13. Single crystal x-ray was used to determine the absolute configuration of the chiral compounds.
14. Tizabi Y., Russell L.T., Johnson M., and Darmani N.A. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 1445
15. Singh P., and Kumar R. J. Enzyme Inhib. 16 (2001) 491
16. Castelijns, A.; Dielemans, Hubertus J. EP 564030, 1993.
17. Mitsunobu conditions gave us mainly the compounds with reversed configuration, along with 5-10% of the other isomer.
18. Davephos: CAS number: 213697-53-, 2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)-biphenyl.